# Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer

> **NCT03936218** · PHASE3 · COMPLETED · sponsor: **Eurofarma Laboratorios S.A.** · enrollment: 94 (actual)

## Conditions studied

- Advanced Prostate Cancer

## Interventions

- **DRUG:** Inj. Goserelin (Test) Subcutaneously
- **DRUG:** Inj. Zoladex (Reference) Subcutaneously

## Key facts

- **NCT ID:** NCT03936218
- **Lead sponsor:** Eurofarma Laboratorios S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-30
- **Primary completion:** 2023-11-30
- **Final completion:** 2024-04-01
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2025-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03936218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03936218, "Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03936218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*